Indonesia approves emergency use of China's Zifivax Covid-19 vaccine


JAKARTA, Oct 9 (Xinhua): Indonesia's drug and food authority BPOM has announced that it has issued an emergency use authorization (EUA) for the Zifivax Covid-19 vaccine produced by Chinese biopharmaceutical company Anhui Zhifei Longcom.

"Today, BPOM again announces that we have approved a Covid-19 vaccine product under the trade name Zifivax which was developed with a recombinant protein sub-unit platform," BPOM's head Penny Lukito told a virtual press conference.

Limited time offer:
Just RM5 per month.

Monthly Plan

RM13.90/month
RM5/month

Billed as RM5/month for the 1st 6 months then RM13.90 thereafters.

Annual Plan

RM12.33/month

Billed as RM148.00/year

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Indonesia , Covid-19 , Zifivax , Vaccine , Emergency Use

   

Next In Aseanplus News

Shared call for ceasefire
Eight people reported injured after southwest Japan quake
Woman’s body found with 30 stab wounds
Apple CEO to meet S’pore leaders to wrap Asia tour
Scion PM modernised Singapore
Rains wreak regional havoc
Volcano’s fury sparks tsunami alert
Tripling bilateral trade with NZ on the cards
Papua New Guinea on high-level itinerary
Asean news headlines as at 9pm on Thursday (April 18)

Others Also Read